Physician profile
Kevin Feeley
NPI 1881219822
$2,376.64
in general payments reported to CMS, 2019-2025
23 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $31.42 · 2023: $282 · 2024: $833 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,345.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $697.77 | 2023-2025 | |
| Novo Nordisk INC | $391.23 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $154.23 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $131.69 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $129.54 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.12 | 2024-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $103.98 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.71 | 2025 | Caplyta |
| Amgen INC. | $97.13 | 2023-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $61.76 | 2023-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $59.29 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $44.91 | 2022-2025 | Proquad, Gardasil 9, Vaxelis |
| Exact Sciences Corporation | $40.73 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $35.36 | 2023-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $32.83 | 2024-2025 | Farxiga |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.89 | 2024-2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $28.85 | 2024 | Gvoke Hypopen |
| Corcept Therapeutics | $23.95 | 2023 | Korlym |
| Ironwood Pharmaceuticals, INC | $22.17 | 2024 | |
| Alkermes, INC. | $21.26 | 2025 | Vivitrol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.16 | 2025 | Jardiance |
| Inspire Medical Systems, INC. | $13.58 | 2024 | Inspire |
| Lundbeck LLC | $13.50 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Feeley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.